Pharma Focus Asia

Piramal Pharma to Expand its Aurora Facility in Canada

Introduction:

Piramal Pharma Solution's business is investing US$188 million for the expansion of its Aurora facility in Canada.

Features:

The expansion will add a new state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients (APIs).

The new facility will utilise ~10,500 sq. ft. of new manufacturing space and will enhance its offerings to customers with this new addition.

It will also support the manufacture of HPAPIs down to an Occupational Exposure Limit (OEL) of 1mcg/ m3.

The expansion will also include two new reactor suites, a dedicated filter dryer room, and a portable filter dryer.

Apart from these, it will also include filtration and drying capabilities that will increase service offerings at the Piramal Pharma Solutions Aurora facility.

The expansion is expected to be completed and be operational by April 30, 2021.

Specifications:

NamePiramal Pharma
TypeExpansion
BudgetUS$188 million
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference